Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).
Hua Medicine ("the Company", stock code: 2552.HK) announced today that it will present the research results of dorzagliatin, the Company's global first-in-class glucokinase activator (GKA), at the 85th American Diabetes Association (ADA) Scientific Sessions.
On May 9, at the Commendation Conference for Model Collectives, Model Workers, and Advanced Workers in Shanghai, Dr. Zhang Yi, the Senior Vice President of the Drug Development Department and Chief Medical Officer of Hua Medicine, was honored as a "Shanghai Model Worker and Advanced Worker" for her outstanding contributions in the field of medical research and development.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
